Navigation Links
ArunA Biomedical Announces Exclusive Worldwide Technology Licensing Agreement to Commercialize Human Embryonic Stem Cell Derived Mesenchymal Cells

ATHENS, Georgia, Aug. 19 /PRNewswire/ -- ArunA Biomedical, Inc., a leader in human embryonic stem cell derived products, announced today that it has entered into an exclusive worldwide technology licensing agreement with the University of Georgia Research Foundation that will enable the company to commercialize human mesenchymal cells developed at the University of Georgia.

(Logo: )

Under the terms of the agreement, ArunA has acquired an exclusive worldwide license to develop and commercialize human mesenchymal cells (hMSC(TM)) derived from human embryonic stem cells, a product never before available. ArunA will offer the academic and industrial research communities access to a highly uniform population of human mesenchymal cells grown as adherent monolayer cultures in multiple turn-key kit formats. The hMSC kits will provide a physiologically relevant and genetically stable source of research material for use in a broad range of life science research applications such as: developmental pathway studies, disease modeling, in vitro toxicology, compound screening and humanized animal models.

"ArunA's proprietary adherent monolayer culture technology creates millions of highly uniform cells. These unique cells provide researchers with new enabling tools that can have a measurable impact on the advancement of drug discovery," says ArunA Biomedical President and Chief Executive Officer, William Sharp. "We are targeting an early first quarter 2009 launch of ArunA's first hMSC kit."

According to Robert Nerem, the Parker H. Petit Distinguished Chair for Engineering in Medicine at the Georgia Institute of Technology, "One of the most important uses of human embryonic stem cells will be in the generation of uniform populations of adult stem cells and progenitor cells. It is thus exciting that ArunA Biomedical will be able to provide uniform cell populations of human mesenchymal cells in kit form. This not only will be of value to bench scientists, but also in advancement toward clinical therapies."

About ArunA Biomedical

Located in Athens, Georgia, ArunA Biomedical, Inc. is a privately held biotechnology corporation dedicated to the discovery, manufacturing and commercialization of emerging new technologies in human stem cell research for use in drug discovery and basic research. ArunA is the first company to commercialize products derived from human embryonic stem cells and sees its proprietary technology as a catalyst leading to the discovery of novel therapeutic compounds, tests for neurotoxicity and breakthroughs in understanding human development and diseases.

SOURCE ArunA Biomedical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. ArunA Biomedical Names William T. Sharp President and Chief Executive Officer
2. Vista Partners Updates Coverage on Inovio Biomedical Corporation (Amex: INO); $3.57 Price Target
3. Roche and Response Biomedical Corporation Aim to Reduce Vein-to-Brain Time with New Point-of-Care Cardiac Tests
4. Frontage Laboratories Completes Acquisition of Advanced Biomedical Research, Inc. (ABR)
5. Medicare Exemplary Provider Accreditation Awarded to Regenesis Biomedical
6. HIPAA Privacy Rule Impedes Biomedical Research
7. Ten Latin American Scientists Named 2008 Pew Fellows in the Biomedical Sciences
8. Environmental Tectonics Corporations BioMedical Systems Division Awarded Contract for Multiple Monoplace Chambers
9. The NCIIA Recognizes Collegiate Biomedical Engineering Innovations
10. Regenesis Biomedical Appoints Scientific Advisory Board Composed of Life Science and Electronics Experts
11. Professors Marc Feldmann and Sir Ravinder Maini Named Winners of the 2008 Dr. Paul Janssen Award for Biomedical Research
Post Your Comments:
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... is pleased to announce the launch of their brand, UP4™ Probiotics, into Target ... over 35 years, is proud to add Target to its list of well-respected ...
(Date:6/23/2016)... 23, 2016 Houston Methodist Willowbrook Hospital ... Sports Association to serve as their official health ... Methodist Willowbrook will provide sponsorship support, athletic training ... association coaches, volunteers, athletes and families. ... Sports Association and to bring Houston Methodist quality ...
(Date:6/23/2016)... --  EpiBiome , a precision microbiome engineering company, today ... from Silicon Valley Bank (SVB). The financing will allow ... drug development efforts, as well as purchase additional lab ... been an incredible strategic partner to us – one ... provide," said Dr. Aeron Tynes Hammack , EpiBiome,s ...
(Date:6/23/2016)... LOUISVILLE, Ky. , June 23, 2016 /PRNewswire/ ... from two Phase 1 clinical trials of its ... double-blind, placebo-controlled, single and multiple ascending dose studies ... and pharmacodynamics (PD) of subcutaneous injection in healthy ... APL-2 subcutaneously (SC) either as a single dose ...
Breaking Biology Technology:
(Date:4/15/2016)... CHICAGO , April 15, 2016  A ... companies make more accurate underwriting decisions in a ... offering timely, competitively priced and high-value life insurance ... health screenings. With Force Diagnostics, rapid ... and lifestyle data readings (blood pressure, weight, pulse, ...
(Date:4/14/2016)... , April 14, 2016 ... Malware Detection, today announced the appointment of Eyal ... new role. Goldwerger,s leadership appointment comes at ... heels of the deployment of its platform at several ... biometric technology, which discerns unique cognitive and physiological factors, ...
(Date:3/31/2016)... 31, 2016   ... the "Company") LegacyXChange is excited to release ... soon to be launched online site for trading 100% ... ) will also provide potential shareholders a sense of ... to an industry that is notorious for fraud. The ...
Breaking Biology News(10 mins):